Form 4: TransMedics Group Executive Tamer Khayal Executes Stock Options and Sells Shares

Sentiment:

SEC Form 4 Filing


Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan on August 1, 2024.

Summary

  • On August 1, 2024, Tamer Khayal, the Chief Commercial Officer of TransMedics Group, Inc. (TMDX), executed stock options to acquire 2,958 shares of common stock at prices of $38.46, $66.10, and $13.28.
  • Simultaneously, Khayal sold 2,857 shares of common stock at prices ranging from $151.80 to $166.00.
  • These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on September 6, 2023.
  • Following these transactions, Khayal directly owns 20,843 shares of TransMedics Group, Inc.

Sentiment

Score: 5

Explanation: Neutral sentiment as the filing simply reports insider transactions under a pre-arranged plan.

Industry Context

This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a change in the company's prospects or management's confidence.

Key Dates

DateDescription
09/06/2023Date of entry into Rule 10b5-1 trading plan
08/01/2024Date of transactions (option exercise and share sales)
08/05/2024Date of Form 4 filing
02/20/2027Stock Option Expiration Date
02/22/2026Stock Option Expiration Date
02/24/2025Stock Option Expiration Date

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.